Elara has initiated coverage on four pharmaceutical stocks, assigning Buy, Accumulate and Reduce ratings. Alkem Laboratories emerged as its top pick for margin recovery, while Eris Lifesciences and Mankind Pharma could benefit from portfolio expansion, acquisitions and deleveraging. Elara retained a cautious view on IPCA Laboratories after its recent rally.